Article Text
Abstract
Many children in the USA are prescribed psychotropic drugs that have not been fully investigated in paediatric clinical trials. The common practice of prescribing psychotropic drugs off-label poses unknown and potentially serious short- and long-term consequences for these children. This paper briefly reviews the factors associated with the lack of paediatric clinical trials. We advocate a shift toward increasing paediatric trials with psychotropic drugs through a combination of adequate safety controls, additional reimbursement/compensation, a more organised and large-scale effort to collate results and outcomes across researchers and studies and additional public education about the importance of this research. In addition, we encourage the re-examination of the ethical standards for children's participation in phase 1 clinical trials as well as argue for longitudinal developmental studies on children who are prescribed off-label psychotropic drugs.
- Behavioural research
- philosophical ethics
- psychotherapy
- suicide/assisted suicide
Statistics from Altmetric.com
Read the full text or download the PDF:
Other content recommended for you
- Prerequisites to support high-quality clinical trials in children and young people
- Challenges in clinical trials for children and young people
- Informed consent and assent guide for paediatric clinical trials in Europe
- Non-static framework for understanding adaptive designs: an ethical justification in paediatric trials
- StaR Child Health: developing evidence-based guidance for the design, conduct and reporting of paediatric trials
- A systematic review of paediatric randomised controlled drug trials published in 2007
- Informed consent for paediatric clinical trials in Europe
- Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee
- PRINTO/PRES international website for families of children with rheumatic diseases: www.pediatric-rheumatology.printo.it
- Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary